{
    "clinical_study": {
        "@rank": "166391", 
        "arm_group": [
            {
                "arm_group_label": "1.1 HEALTHY VOLUNTEER RESEARCH  SUBJECTS"
            }, 
            {
                "arm_group_label": "1.2 VOLUNTEER RESEARCH SUBJECTS WITH LUNG DISEASE"
            }, 
            {
                "arm_group_label": "2. WCMC/NYPH CLINICAL PATIENTS"
            }, 
            {
                "arm_group_label": "3. PCNY CLINICAL PATIENTS"
            }
        ], 
        "biospec_descr": {
            "textblock": "This is a protocol to obtain blood, urine and/or airway specimens from normal individuals\n      and individuals with lung disorders in order to carry out laboratory studies looking at\n      genetic expression, gene transfer, infection, proteins, human genes, and to store specimens\n      for future genetic studies. Specimens collected may include blood, urine and airway samples\n      (nasal, airway brushing, biopsy and/or washings) from consenting subjects. Subjects will\n      include both individuals diagnosed with lung disease and healthy control subjects. The\n      purpose of this study is to obtain biologic materials from the blood, airways and/or urine\n      of normal individuals and individuals with lung disease. The normal are used to establish a\n      set of normal ranges for various parameters. These provide control information when compared\n      to individuals with various pulmonary diseases, and will help in understanding of the\n      etiology and pathogenesis of various lung diseases."
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "This is a protocol to obtain blood, urine and/or airway specimens from normal individuals\n      and individuals with lung disorders in order to carry out laboratory studies looking at\n      genetic expression, gene transfer, infection, proteins, human genes, and to store specimens\n      for future genetic studies. Specimens collected may include blood, urine and airway samples\n      (nasal, airway brushing, biopsy and/or washings) from consenting subjects. Subjects will\n      include both individuals diagnosed with lung disease and healthy control subjects. The\n      purpose of this study is to obtain biologic materials from the blood, airways and/or urine\n      of normal individuals and individuals with lung disease. The normal are used to establish a\n      set of normal ranges for various parameters. These provide control information when compared\n      to individuals with various pulmonary diseases, and will help in understanding of the\n      etiology and pathogenesis of various lung diseases. The investigators will use bronchoscopy\n      (inserting a scope into the lungs) to obtain airway cells by brushing, biopsy and/or\n      washings in individuals with lung disease and in healthy controls. By studying those cells,\n      the investigators hope to learn more about the specific causes of lung disease, how lung\n      disease manifests and progresses, and how lung disease can be treated."
        }, 
        "brief_title": "Collection of Airway, Blood and/or Urine Specimens From Subjects for Research Studies", 
        "completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Chronic Obstructive Pulmonary Disease (COPD)", 
            "Asthma", 
            "Smoking", 
            "Smoking Cessation", 
            "Healthy Smoker"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Asthma", 
                "Lung Diseases", 
                "Respiration Disorders", 
                "Pulmonary Disease, Chronic Obstructive", 
                "Smoking", 
                "Lung Diseases, Obstructive"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Group 1.1\n\n          -  All study subjects should be able to provide informed consent\n\n          -  Males or females ages 18 years and older\n\n          -  Must provide HIV informed consent\n\n        Group 1.2\n\n          -  Must provide informed consent\n\n          -  Males and females age 18 years and older\n\n          -  Lung disease proven by at least one of the following: symptoms  consistent with\n             pulmonary disease; (2) chest X-rays consistent with lung disease; (3) pulmonary\n             function tests consistent with lung disease; (4) lung biopsy consistent with lung\n             disease; (5) family history of lung disease; and/or (6) diseases of organs with known\n             association with lung disease\n\n          -  Must provide HIV informed consent\n\n        Group 2\n\n          -  Must provide informed consent\n\n          -  Males and females, age 18 years and older\n\n          -  Lung disease proven by at least one of the following: (1) symptoms consistent with\n             pulmonary disease; (2) chest X-rays consistent with lung disease; (3) pulmonary\n             function tests consistent with lung disease; (4) lung biopsy consistent with lung\n             disease; (5) family history of lung disease; and (6) diseases of organs with known\n             association with lung disease\n\n        Group 3\n\n          -  Must provide informed consent\n\n          -  Males and females, age 18 years and older\n\n          -  Lung disease proven by at least one of the following: symptoms consistent with\n             pulmonary disease; (2) chest X-rays consistent with lung disease; (3) pulmonary\n             function tests consistent with lung disease; (4) lung biopsy consistent with lung\n             disease; (5) family history of lung disease; and (6) diseases of organs with known\n             association with lung disease\n\n        Exclusion Criteria:\n\n        Group 1.1\n\n          -  Individuals not deemed in good overall health by the investigator will not be\n             accepted into the study.\n\n          -  Habitual use of drugs and/or alcohol within the past six months (Acceptable:\n             Marijuana one time in three months; average of two alcoholic beverages per day; drug\n             and/or alcohol abuse is defined as per the DSM-IV Substance Abuse Criteria).\n\n          -  Individuals with history of chronic lung disease, including asthma or with recurrent\n             or recent (within three months) acute pulmonary disease will not be accepted into the\n             study.\n\n          -  Individuals with allergies to atropine or any local anesthetic will not be accepted\n             into the study.\n\n          -  Individuals with allergies to pilocarpine, isoproterenol, terbutaline, atropine or\n             aminophylline will not be accepted into the study.\n\n          -  Females who are pregnant or nursing will not be accepted into the study\n\n        Group 1.2\n\n          -  Any history of allergies to xylocaine, lidocaine, versed, valium, atropine,\n             pilocarpine, isoproterenol, terbutaline, aminophylline, or any local anesthetic will\n             not be included in the study\n\n          -  Habitual use of drugs and/or alcohol within the past six months (Acceptable:\n             Marijuana one time in three months; average of two alcoholic beverages per day; drug\n             and/or alcohol abuse is defined as per the DSM-IV Substance Abuse Criteria)\n\n          -  Females who are pregnant or nursing\n\n        Group 2\n\n          -  Patient refuses consent\n\n        Group 3\n\n          -  Patient refuses consent"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "New York Metropolitan area residents"
            }
        }, 
        "enrollment": {
            "#text": "2000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 10, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01776398", 
            "org_study_id": "1204012331", 
            "secondary_id": "1R01HL107882-01"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "COPD", 
            "Chronic Obstructive Pulmonary Disease", 
            "Lung disease", 
            "Emphysema", 
            "Smoking", 
            "Smoking Cessation", 
            "Quit Smoking", 
            "Healthy Smoker", 
            "Smoker", 
            "Non-smoker"
        ], 
        "lastchanged_date": "October 25, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10065-4870"
                }, 
                "name": "Weill Cornell Medical College and Weill Cornell Medical Center, Department of Genetic Medicine"
            }, 
            "investigator": [
                {
                    "last_name": "Ben-Gary Harvey, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Ann Tilley, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Robert Kaner, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Daniel Libby, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Brian Gelbman, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Jenny Yee-Levin, P.A.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Malesa Pereira, BA", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Dorothy Ryan, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Ida Cao, BA", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Mitch Greene, MA", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "4", 
        "official_title": "Collection of Airway, Blood and/or Urine Specimens From Subjects for Research Studies", 
        "overall_contact": {
            "email": "chollman@med.cornell.edu", 
            "last_name": "Charleen Hollman, PhD, MPA, RN", 
            "phone": "646-962-2672"
        }, 
        "overall_contact_backup": {
            "email": "mig2037@med.cornell.edu", 
            "last_name": "Mitch Greene, MA", 
            "phone": "646-962-2672"
        }, 
        "overall_official": {
            "affiliation": "Weill Medical College of Cornell University", 
            "last_name": "Ronald G. Crystal, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary endpoint of the study is to obtain biologic materials from the blood, airways and/or urine of normal individuals and individuals with lung disease. The normal are used to establish a set of normal ranges for various parameters. These provide control information when compared to individuals with various pulmonary diseases, and will help in understanding the etiology and pathogenesis of various lung diseases.", 
            "measure": "Establishing normal ranges for various parameters", 
            "safety_issue": "No", 
            "time_frame": "Participants upon completing the study will be followed up by a phone call seven days after their visit."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01776398"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Weill Medical College of Cornell University", 
        "sponsors": {
            "collaborator": {
                "agency": "National Heart, Lung, and Blood Institute (NHLBI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Weill Medical College of Cornell University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Observational Model: Case Control, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "October 2013"
    }
}